Articoli correlati a Tumors of the Central Nervous System: Gliomas: Glioblastoma...

Tumors of the Central Nervous System: Gliomas: Glioblastoma (2) - Rilegato

 
9789400706170: Tumors of the Central Nervous System: Gliomas: Glioblastoma (2)
Vedi tutte le copie di questo ISBN:
 
 
Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients with high-grade gliomas is clarified. The advantage of the use of intraoperative low-field MRI in glioma surgery is explained.

Le informazioni nella sezione "Riassunto" possono far riferimento a edizioni diverse di questo titolo.

Contenuti:

Chapter 1. INTRODUCTION. I. BIOMARKERS AND DIAGNOSIS. Chapter  2. GLIOMAGENESIS: ADVANTAGES AND LIMITATIONS OF BIOMARKERS. Chapter  3. MOLECULAR SUBTYPES OF GLIOMAS. Chapter  4. GLIOBLASTOMA: GERMLINE MUTATION OF TP53. Chapter  5. GLIOMAS: ROLE OF THE TP53 GENE. Chapter  6. THE ROLE OF IDH1 AND IDH2 MUTATIONS IN MALIGNANT GLIOMAS. Chapter  7. MALIGNANT GLIOMA: ISOCITRATE DEHYDROGENASES 1 AND 2  MUTATIONS. Chapter  8. METABOLIC DIFFERNCES IN DIFFERENT REGIONS OF GLIOMA SAMPLES. Chapter  9. GLIOBLASTOMA PATIENTS: ROLE OF METHYLATED MGMT. Chapter  10. BRAIN TUMOR ANGIOGENESIS AND GLIOMA GRADING: ROLE OF TUMOR BLOOD VOLUME AND PERMEABILITY ESTIMATES USING PERFUSION CT. Chapter 11.  VASCULOGENIC MIMICRY IN GLIOMA. Chapter 12. NEWLY DIAGNOSED GLIOMA: DIAGNOSIS USING POSITRON EMISSION TOMOGRAPHY WITH METHIONINE AND FLUOROTHYMIDINE. Chapter  13. ROLE OF DIFFUSION TENSOR IMAGING IN DIFFERENTIATION OF GLIOBLASTOMAS FROM  SOLITARY BRAIN METASTASES. Chapter  14. I-TM-601 SPECT IMAGING OF HUMAN GLIOMA. Chapter  15. ASSESSMENT OF BIOLOGICAL TARGET VOLUME USING POSITRON EMISSION TOMOGRAPHY IN HIGH-GRADE GLIOMA PATIENTS. Chapter  16. SKIN METASTASES OF GLIOBLASTOMA. II. THERAPY. Chapter 17. DIFFUSE LOW-GRADE GLIOMAS. WHAT DOES “COMPLETE RESECTION” MEAN? Chapter 18. QUANTITATIVE APPROACH OF THE NATURAL COURSE OF DIFFUSE LOW-GRADE GLIOMAS. Chapter  19. IMPACT OF RESECTION EXTENT ON OUTCOMES IN PATIENTS WITH HIGH-GRADE GLIOMAS. Chapter 20. RECURRENT MALIGNANT GLIOMAS: 5-AMINOLEVULINIC ACID FLUORESCENCE-GUIDED RESECTION. Chapter 21. GLIOMA SURGERY: INTRAOPERATIVE LOW FIELD MAGNETIC RESONANCE IMAGING. Chapter  22. LOW-GRADE GLIOMAS: INTRAOPERATIVE ELECTRICAL STIMULATIONS. Chapter  23. MALIGNANT GLIOMAS: PRESENT AND FUTURE THERAPEUTIC DRUGS. Chapter 24. RECURRENT MALIGNANT GLIOMA PATIENTS: TREATMENT WITH CONFORMAL RADIOTHERAPY AND SYSTEMIC THERAPY. Chapter  25. GLIOBLASTOMA: BORON NEUTRON CAPTURE THERAPY. Chapter  26. GLIOBLASTOMA: ANTI-TUMOR ACTION OF CYCLOSPORINE A AND FUCTIONALLY RELATED DRUGS.Chapter 27. GLIOBLASTOMA PATIENTS: CHEMOTHERAPY WITH CISPLATIN, TEMOZOLOMIDE AND THALIDOMIDE. Chapter  28. GLIOBLASTOMA : ROLE OF GALECTIN- 1 IN CHEMORESISTANCE. Chapter  29. GLIOMA-INITIATING CELLS: INTERFERON TREATMENT. Chapter  30. GLIOBLASTOMA : ANTITUMOR ACTION OF NATURAL AND SYNTHETIC  CANNABINOIDS. Chapter  31. PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: THERAPY WITH COMBINATION OF BEVACIZUMAB AND IRINOTECAN. Chapter 32. MONITORING GLIOMAS IN VIVO USING DIFFUSION- WEIGHTED MRI DURING GENE THREAPY –INDUCED APOPTOSIS. Chapter 33. HIGH-GRADE GLIOMAS: DENDRITIC CELL THERAPY. Chapter 34. GLIOBLASTOMA MULTIFORME: USE OF ADENOVIRAL VECTORS. Chapter 35. FISCHER-F98 GLIOMA MODEL: METHODOLOGY. Chapter  36. CELLULAR CHARACTERIZATION OF ANTI-VEGF AND IL-6 THERAPY IN EXPERIMENTAL  GLIOMA. Chapter  37. ADULT BRAINSTEM GLIOMAS: DIAGNOSIS AND TREATMENT . Chapter  38. USE OF LOW MOLECULAR WEIGHT HEPARIN IN THE TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISEASE IN GLIOMA PATIENTS. III. PROGNOSIS. Chapter 39. BRAINSTEM GLIOMAS: AN OVERVIEW. Chapter  40. TUMOR-ASSOCIATED EPILEPSY IN PATIENTS WITH GLIOMA. Chapter 41. CHRONIC EPILEPSY ASSOCIATED WITH BRAIN TUMORS: SURGICAL NEUROPATHOLOGY. Chapter 42. LOW-GRADE GLIOMAS: ROLE OF RELATIVE CEREBRAL BLOOD VOLUME IN MALIGNANT TRANSFORMATION. Chapter 43. ANGIOCENTRIC GLIOMA- INDUCED SEIZURES: LESIONECTOMY.

Le informazioni nella sezione "Su questo libro" possono far riferimento a edizioni diverse di questo titolo.

  • EditoreSpringer Nature
  • Data di pubblicazione2011
  • ISBN 10 9400706170
  • ISBN 13 9789400706170
  • RilegaturaCopertina rigida
  • Numero edizione1
  • Numero di pagine480
  • RedattoreHayat M. A.

Spese di spedizione: EUR 48,99
Da: Germania a: U.S.A.

Destinazione, tempi e costi

Aggiungere al carrello

Altre edizioni note dello stesso titolo

9789400735804: Tumors of the Central Nervous System, Volume 2: Gliomas: Glioblastoma (Part 2)

Edizione in evidenza

ISBN 10:  ISBN 13:  9789400735804
Casa editrice: Springer, 2013
Brossura

I migliori risultati di ricerca su AbeBooks

Immagini fornite dal venditore

Hayat, M. A.
Editore: Springer Netherlands (2011)
ISBN 10: 9400706170 ISBN 13: 9789400706170
Nuovo Rilegato Quantità: > 20
Print on Demand
Da:
moluna
(Greven, Germania)
Valutazione libreria

Descrizione libro Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. 1. Targeted therapy determined by molecular genetics is emphasized. 2.Several imaging techniques for diagnosis and treatment assessment are detailed. 3.Present and future therapeutic drugs against malignant gliomas are described. 4.The anti-tumor action of . Codice articolo 5825375

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 180,07
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 48,99
Da: Germania a: U.S.A.
Destinazione, tempi e costi
Immagini fornite dal venditore

M. A. Hayat
ISBN 10: 9400706170 ISBN 13: 9789400706170
Nuovo Rilegato Quantità: 2
Print on Demand
Da:
BuchWeltWeit Ludwig Meier e.K.
(Bergisch Gladbach, Germania)
Valutazione libreria

Descrizione libro Buch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients with high-grade gliomas is clarified. The advantage of the use of intraoperative low-field MRI in glioma surgery is explained. 480 pp. Englisch. Codice articolo 9789400706170

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 213,99
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 23,00
Da: Germania a: U.S.A.
Destinazione, tempi e costi
Immagini fornite dal venditore

M. A. Hayat
Editore: Springer Netherlands (2011)
ISBN 10: 9400706170 ISBN 13: 9789400706170
Nuovo Rilegato Quantità: 1
Da:
AHA-BUCH GmbH
(Einbeck, Germania)
Valutazione libreria

Descrizione libro Buch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Advantages and limitations of biomarkers in gliomagenesis are described. Molecular subtypes of gliomas are detailed. The role played by TP53 gene mutation in the deadliest brain tumor, glioblastoma multiforme, is pointed out. The role of mutations of IDH1 and IDH2, and isocitrate dehydrogenases in malignant gliomas are presented. Metabolic differences in different regions of the glioma tumor are clarified. Various types of imaging modalities, including PET and SPECT, to diagnose gliomas in general and glioblastoma in particular in patients are explained in detail. Both low-grade and high-grade gliomas are discussed. Conventional as well as fluorescent-guided resection techniques for high-grade, recurrent malignant gliomas are detailed. Impact of resection extent on outcomes in patients with high-grade gliomas is clarified. The advantage of the use of intraoperative low-field MRI in glioma surgery is explained. Codice articolo 9789400706170

Informazioni sul venditore | Contatta il venditore

Compra nuovo
EUR 217,79
Convertire valuta

Aggiungere al carrello

Spese di spedizione: EUR 32,99
Da: Germania a: U.S.A.
Destinazione, tempi e costi